OUTSOURCED PHARMA CAPACITY UPDATE LARGE MOLECULE VIDEOS
Northway Biotech Capacity Update January 2025: Large Molecule Development
Over the past 20 years, we have completed more than 175 successful projects around the globe, showcasing our commitment to quality and customer satisfaction.
Mabion Capacity Update January 2025: Large Molecule Development
Go on a virtual tour of our GMP-certified facility, where we uphold our expanded capabilities for large molecule development to the highest standards for clinical and commercial manufacturing.
KBI Biopharma Capacity Update January 2025: Large Molecule Development
Follow along as Derek Ryan, Sr. Director of Analytical Development, showcases our high-throughput technology and digital tools for process understanding and optimizing decision-making.
Cytovance Biologics Capacity Update January 2025: Large Molecule Development
Join Rose Rhomberg, Senior Business Development Director, as she showcases Cytovance’s microbial and mammalian capabilities, along with our available manufacturing capacity.
Catalent Capacity Update January 2025: Large Molecule Development
Learn how our expertise and advanced capabilities provide customized analytical solutions that ensure quality, precision, and regulatory compliance for your biotherapeutics.
Northway Biotech Capacity Update October 2024: Large Molecule Drug Substance
We have the capabilities, competitive advantages, and capacity to onboard new projects across two facilities: Waltham, MA, operational since 2020, and Vilnius, Lithuania, established in 2004.
Cytovance Biologics Capacity Update October 2024: Large Molecule Drug Substance
Senior Business Development Director Rose Rhomberg presents an in-depth look at Cytovance’s capabilities and highlights the available capacity designed to accelerate your goals.
Novartis Contract Manufacturing Capacity Update October 2024: Large Molecule Drug Substance
Gain valuable insights into our mammalian development services, manufacturing solutions, upcoming capacity availability, as well as updates on expansion timelines for external clients.
Curia Capacity Update October 2024: Large Molecule Drug Substance
We offer adaptable, comprehensive solutions to advance your program seamlessly from IND-enabling studies through to late-stage commercial production.
Pfizer CentreOne Capacity Update October 2024: Large Molecule Drug Substance
See how our specialized manufacturing site in Sanford, NC — backed by over 35 years of expertise in mAb production — can expedite the delivery of your groundbreaking therapies to patients.
Resilience Capacity Update October 2024: Large Molecule Drug Substance
Business Head of Biologics and Vaccines Evan Pasenello shares how Resilience’s innovative platforms and specialized expertise can effectively support your development and manufacturing programs.
Boehringer Ingelheim BioXcellence™ Capacity Update October 2024: Large Molecule Drug Substance
Explore our global production network, advanced aseptic filling, in-house analytics, and the expertise that has driven 47 biopharmaceuticals to market success.
FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Large Molecule Drug Substance
Rasmus Pedersen, Ph.D., outlines strategies to expand large-molecule production capacity to meet the global medicine demand, noting the current gap that leaves 2 billion people without access.
Samsung Biologics Capacity Update October 2024: Large Molecule Drug Substance
We're poised to be your next growth engine with our commitment to quality, speed, and agility, as we expand our facilities and invest in innovative modalities to meet your large molecule needs.
Cytovance Capacity Update July 2024: Large Molecule Development
Centrally located in the United States, with a decades-long history in biologics development and manufacturing, Cytovance delivers ingenuity end-to-end to both large pharma and biotech clients alike.
ATON Bio Capacity Update July 2024: Large Molecule Development
Gain insights into boosting efficiency, fostering innovation, and how integrated capabilities generate value for innovators.
Curia Capacity Update July 2024: Large Molecule Development
Curia Biologics can be a critical partner for small, midsize, and even large biotech businesses to support all requirements from IND through late stage commercial programs.
Mabion Capacity Update July 2024: Large Molecule Development
Explore our new installations in upstream development, bioreactors, and fill-finish. This state of the art EU-GMP facility is staffed by a team of 250 professionals, and capacity is now available.
Novartis Contract Manufacturing Capacity Update July 2024: Large Molecule Development
Review our capabilities in tech transfer, clinical drug substance, and commercial drug substance manufacturing across our manufacturing network in Singapore, Europe, and the US.
AbbVie Capacity Update July 2024: Large Molecule Development
Delve into the intricacies of biopharmaceutical manufacturing, focusing on stages such as CLD, fermentation, and purification. We also explore process optimization and scale-up techniques.
Scorpius Biomanufacturing Capacity Update July 2024: Large Molecule Development
Scorpius' VP of Manufacturing Operations Matt LeClair presents a 3D virtual tour of the process development lab, analytical and QC lab, and the mammalian manufacturing upstream and cell culture suites.
KBI Biopharma Capacity Update May 2024: Large Molecule Development
Discover how our development and platform-based manufacturing solutions can create an unobstructed path to market for your large molecule pipeline in a dynamic regulatory environment.
JOINN Biologics Capacity Update May 2024: Large Molecule Development
JOINN Biologics US Inc. is a California-based CDMO that provides our customers with flexible solutions for complex biologics, including ADCs. JOINN Biologics is a combination of "Big Pharma Infrastructure" with 200L and 1000L traditional stainless steel bioreact...
EirGenix Capacity Update May 2024: Large Molecule Development
EirGenix has immediate capacity availability up to 12 x 2,000 L SUBs for mammalian cells and up to 150 L scale for microbial. The microbial capacity will increase to 350L and 1,000L by 2025.
Singota Solutions Capacity Update May 2024: Large Molecule Development
Review our Analytical, Product and Process Development, and Manufacturing capabilities along with the knowledge required to demonstrate product and process understanding.
AGC Biologics Capacity Update May 2024: Large Molecule Development
Learn more about our global Biologics network, track record, and capabilities. Plus, take a detailed look at our Copenhagen site and how we balance flexibility with scale to meet the demands of clients.
Scorpius Biomanufacturing Capacity Update May 2024: Large Molecule Development
Our facility offers ~2,000 sq. ft. of process and analytical development labs and ~8,600 sq. ft. of cGMP-compliant cleanroom manufacturing space for mammalian and microbial programs.
Mabion Capacity Update May 2024: Large Molecule Development
Review our installations in upstream development, downstream development, and fill & finish. Our EU-GMP certified facility is staffed by a team of 250 professionals and focuses on providing CDMO services.
Don't miss our next installment!
These conferences are ideal for professionals who have the authority to choose and manage CDMO relationships and need to secure capacity for their development or commercial programs.
How can we help?
Are you a supplier looking to present at our next event?